-+ 0.00%
-+ 0.00%
-+ 0.00%

Autolus Therapeutics Announces Preliminary Q4 2025 AUCATZYL Revenue Of $24M And $75M For Full Year, Issues 2026 Revenue Outlook Of $120M–$135M

Benzinga·01/12/2026 12:08:26
Listen to the news
  • Company expects preliminary unaudited AUCATZYL net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025
  • Autolus anticipates full year 2026 AUCATZYL net product revenue of $120 million to $135 million
  • Independent real-world AUCATZYL data from ROCCA consortium confirm high level of clinical activity with favorable safety profile
  • Focus for 2026 is:
    • Driving AUCATZYL top line growth
    • Optimizing manufacturing operation to improve gross margin and innovating on next generation manufacturing platform
    • Progressing the CATULUS, LUMINA and BOBCAT trials to expand the utility of obe-cel in pediatric hem-oncology and autoimmune indications